Yes - he did say this month was the timeframe for the HOT IND filing. The question is will they PR it? Even if it's only the filing, I would still think its a positive given the NTGN IPO.
Ken's statement about the CMO being the most important addition to understanding getting a drug from concept to clinical was mind blowing. What in the world was ADXS doing for 2 years without one? Makes me think they actually were trying to sell the company but things fell through. IDK anymore. It certainly seems very amateurish over there. Hopefully Ken gets us back on the map.